Tissue-repair research
BPC-157: Potential Benefits, Research, Risks and Safety
Synthetic peptide discussed in preclinical research; not an FDA-approved medicine.
Overview
BPC-157 is discussed in laboratory and animal research. This listing does not claim that it repairs tissue, treats injury, or has established clinical benefits in people.
How it works
Proposed biological mechanisms in preclinical literature do not establish a safe or effective treatment in humans.
Uses described in the source
Research discussions include tissue-related questions, but reliable evidence is insufficient to establish a clinical use. FDA reports limited safety-related information for proposed compounded routes.
Evidence
Insufficient evidence for established human clinical use
Regulatory status
No FDA-approved indication is identified here. FDA has listed BPC-157 among bulk substances that may present significant safety risks in compounding; this is U.S. information, not a determination of Colombian status.
Safety
FDA cites potential immunogenicity risks for certain routes, peptide-related impurities, API-characterization complexity, and limited safety information. Safety and effectiveness for human treatment are not established.
YouMedicine availability
Investigational / educational only. No treatment availability is claimed.
Sources
Do not use research summaries to self-treat or to infer that a product is suitable, approved, or legally available.